Debiopharm taps Singapore expertise for epigenetic drug discovery deal
This article was originally published in Scrip
Debiopharm has entered into a basic research collaboration with the Experimental Therapeutics Centre (ETC) of Singapore's Agency for Science, Technology and Research (A*STAR), to develop oral small molecule modulators of epigenetic function.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.